CLN-081 is an oral medication being studied for the treatment of non-small cell lung cancer. It specifically targets lung cancers that have certain genetic changes called EGFR exon 20 insertion mutations. This medication is designed to work in patients whose cancer has already been treated with platinum-based chemotherapy. It works by blocking specific signals that cancer cells use to grow and spread.

The study also includes food interaction testing to understand how the medication works when taken with and without high-fat meals. This helps determine the best way to take the medication with respect to meals for optimal effectiveness.

Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations – A specific type of lung cancer that develops when certain genetic changes occur in the EGFR gene. This rare form of lung cancer begins in the larger lung cells and is characterized by specific mutations in the exon 20 region of the EGFR gene. The disease affects the lungs’ ability to function normally and can spread to other parts of the body. The condition develops when lung cells begin to grow uncontrollably due to these specific genetic mutations. This particular variant represents a distinct subset of non-small cell lung cancer with unique characteristics.